{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:26:06Z","timestamp":1772119566549,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-025-10329-2","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:06:55Z","timestamp":1737554815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of radiotherapy in treating local recurrence concomitant with distant metastasis of nasopharyngeal carcinoma: a long-term retrospective multicenter study"],"prefix":"10.1007","volume":"42","author":[{"given":"Lu","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyou","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangjian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyi","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangkun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"10329_CR1","unstructured":"GLOBOCAN cancer statistics https:\/\/gco.iarc.fr\/today\/factsheets-cancers"},{"key":"10329_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.oraloncology.2018.02.011","volume":"79","author":"H Peng","year":"2018","unstructured":"Peng H, Tang LL, Chen BB et al (2018) Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma: a big-data intelligence platform-based analysis[J]. Oral Oncol 79:40\u201346","journal-title":"Oral Oncol"},{"issue":"12","key":"10329_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu GQ et al (2019) Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma[J]. N Engl J Med 381(12):1124\u20131135","journal-title":"N Engl J Med"},{"issue":"12","key":"10329_CR4","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1002\/hed.26836","volume":"43","author":"D Ethan Newton","year":"2021","unstructured":"Ethan Newton D, Valenzuela J, Foley et al (2021) Outcomes for the treatment of locoregional recurrent nasopharyngeal cancer: a systematic review and pooled analysis[J]. Head Neck 43(12):3979\u20133995","journal-title":"Head Neck"},{"key":"10329_CR5","doi-asserted-by":"crossref","unstructured":"Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M et al (2023) Recurrent\/Metastatic nasopharyngeal carcinoma treatment from Present to Future: where are we and where are we heading? [J]Curr treat options Oncol. 15(9):1138\u20131166","DOI":"10.1007\/s11864-023-01101-3"},{"issue":"9","key":"10329_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","volume":"6","author":"R You","year":"2020","unstructured":"You R, Liu YP, Huang PY et al (2020) Efficacy and Safety of Locoregional Radiotherapy with Chemotherapy vs chemotherapy alone in De Novo metastatic nasopharyngeal Carcinoma[J]. JAMA Oncol 6(9):1345\u20131352","journal-title":"JAMA Oncol"},{"key":"10329_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/cac2.12004","volume":"40","author":"XS Sun","year":"2020","unstructured":"Sun XS, Liu SL, Liang YJ et al (2020) The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: a propensity score matching study[J]. Cancer Commun 40:32\u201342","journal-title":"Cancer Commun"},{"key":"10329_CR8","doi-asserted-by":"publisher","first-page":"175883592097813","DOI":"10.1177\/1758835920978132","volume":"12","author":"LL Zhang","year":"2020","unstructured":"Zhang LL, Xu F, He WT et al (2020) Development and validation of a prognostic nomogram for the pre-treatment prediction of early metachronous metastasis in endemic nasopharyngeal carcinoma: a big-data intelligence platform-based analysis[J]. Ther Adv Med Oncol 12:1758835920978132","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10329_CR9","doi-asserted-by":"publisher","first-page":"e0146771","DOI":"10.1371\/journal.pone.0146771","volume":"11","author":"J Wei Zheng","year":"2016","unstructured":"Wei Zheng J, Zong C, Huang et al (2016) Multimodality Treatment May improve the Survival rate of patients with metastatic nasopharyngeal carcinoma with good performance Status[J]. PLoS ONE 11(1):e0146771","journal-title":"PLoS ONE"},{"issue":"1","key":"10329_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13014-023-02310-8","volume":"18","author":"L Li","year":"2023","unstructured":"Li L, Chen L, Yan L et al (2023) Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent\/ metastatic head and neck squamous cell carcinoma patients[J]. Radiat Oncol 18(1):109","journal-title":"Radiat Oncol"},{"key":"10329_CR11","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Head and Neck Cancers Version.2.2023"},{"key":"10329_CR12","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S et al (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, openlabel, phase 3 trial[J]. Lancet 388:1883\u20131892","journal-title":"Lancet"},{"key":"10329_CR13","doi-asserted-by":"crossref","unstructured":"Shaodong HY, Zhang,Gengsheng, Yu et al (2021) Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study[J]. J Clin Oncol.;39(29):3273\u20133282","DOI":"10.1200\/JCO.21.00396"},{"issue":"36","key":"10329_CR14","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"S-H Chiun Hsu","year":"2017","unstructured":"Chiun Hsu S-H, Lee SE et al (2017) Safety and Antitumor Activity of Pembrolizumab in patients with programmed death-ligand 1-Positive nasopharyngeal carcinoma: results of the KEYNOTE-028 Study[J]. J Clin Oncol 35(36):4050\u20134056","journal-title":"J Clin Oncol"},{"issue":"14","key":"10329_CR15","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BY Brigette","year":"2018","unstructured":"Brigette BY, Ma W-T, Lim B-C, Goh et al (2018) Antitumor Activity of Nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) [J]. J Clin Oncol 36(14):1412\u20131418","journal-title":"J Clin Oncol"},{"issue":"6","key":"10329_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"YP Yang","year":"2023","unstructured":"Yang YP, Pan JJ, Wang H et al (2023) Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309) [J]. Cancer Cell 41(6):1061\u20131072e4","journal-title":"Cancer Cell"},{"issue":"8","key":"10329_CR17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"22","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J, Hu C et al (2021) Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol 22(8):1162\u20131174","journal-title":"Lancet Oncol"},{"issue":"9","key":"10329_CR18","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai HQ, Chen QY, Chen DP et al (2021) Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial[J]. Nat Med 27(9):1536\u20131543","journal-title":"Nat Med"},{"issue":"2","key":"10329_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S0360-3016(00)00463-6","volume":"47","author":"TW Leung","year":"2000","unstructured":"Leung TW, Tung SY, Sze WK et al (2000) Salvage brachytherapy for patients with locally persistent nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys 47(2):405\u2013412","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10329_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12916-023-03164-3","volume":"21","author":"DD LiuT","year":"2023","unstructured":"LiuT DD (2023) Radiomic signatures reveal multiscale intratumor heterogeneity associated with tissue tolerance and survival in re-irradiated nasopharyngeal carcinoma: a multicenter study[J]. BMC Med 21(1):464","journal-title":"BMC Med"},{"key":"10329_CR21","first-page":"107087","volume":"159","author":"K Shang","year":"2024","unstructured":"Shang K, Li TT, Chen Y et al (2024) Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a single center prospective phase II clinical trial[J]. Oral on 159:107087","journal-title":"Oral on"},{"issue":"1","key":"10329_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.radonc.2017.03.019","volume":"124","author":"CG Rusthoven","year":"2017","unstructured":"Rusthoven CG, Lanning RM, Jones BL et al (2017) Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy[J]. Radiother Oncol 124(1):139\u2013146","journal-title":"Radiother Oncol"},{"key":"10329_CR23","doi-asserted-by":"publisher","first-page":"110265","DOI":"10.1016\/j.radonc.2024.110265","volume":"196","author":"S Huang","year":"2024","unstructured":"Huang S, Jiang F, Cao C et al (2024) Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: a prospective, single-arm, single-center clinical study[J]. Radiother Oncol 196:110265","journal-title":"Radiother Oncol"},{"key":"10329_CR24","doi-asserted-by":"publisher","first-page":"106583","DOI":"10.1016\/j.oraloncology.2023.106583","volume":"147","author":"ZQ Zhao","year":"2023","unstructured":"Zhao ZQ, Wu YN (2023) Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma[J]. Oral Oncol 147:106583","journal-title":"Oral Oncol"},{"issue":"11","key":"10329_CR25","doi-asserted-by":"publisher","first-page":"101279","DOI":"10.1016\/j.xcrm.2023.101279","volume":"4","author":"SY Chen","year":"2023","unstructured":"Chen SY, Duan XT, Li HF et al (2023) Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: a phase II trial[J]. Cell Rep Med 4(11):101279","journal-title":"Cell Rep Med"},{"key":"10329_CR26","doi-asserted-by":"publisher","first-page":"106695","DOI":"10.1016\/j.oraloncology.2024.106695","volume":"150","author":"L Li","year":"2024","unstructured":"Li L, Chen L, Fan M et al (2024) A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma[J]. Oral Oncol 150:106695","journal-title":"Oral Oncol"},{"key":"10329_CR27","doi-asserted-by":"publisher","first-page":"110311","DOI":"10.1016\/j.radonc.2024.110311","volume":"196","author":"Y Liu","year":"2024","unstructured":"Liu Y, Ma J, Zeng XY et al (2024) Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: a multicenter retrospective study[J]. Radiother Oncol 196:110311","journal-title":"Radiother Oncol"},{"issue":"1","key":"10329_CR28","doi-asserted-by":"publisher","first-page":"e6764","DOI":"10.1002\/cam4.6764","volume":"13","author":"JP Yang","year":"2024","unstructured":"Yang JP, Liao WJ, Su ST et al (2024) Long-term outcomes of metastasis-directed stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma[J]. Cancer Med 13(1):e6764","journal-title":"Cancer Med"},{"issue":"10185","key":"10329_CR29","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet 393(10185):2051\u20132058","journal-title":"Lancet"},{"issue":"10162","key":"10329_CR30","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD et al (2018) Systemic therapy for Advanced or metastatic prostate cancer: evaluation of drug efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial[J]. Lancet 392(10162):2353\u20132366","journal-title":"Lancet"},{"issue":"10192","key":"10329_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"C Yu-Pei","year":"2019","unstructured":"Yu-Pei C, Anthony TCC, Quynh-Thu L et al (2019) Nasopharyngeal carcinoma[J]. Lancet 394(10192):64\u201380","journal-title":"Lancet"},{"issue":"6","key":"10329_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4103\/0973-1482.168181","volume":"11","author":"F Jiang","year":"2015","unstructured":"Jiang F, Jin T, Feng XL et al (2015) Long-term outcomes and failure patterns of patients with nasopharyngeal carcinoma staged by magnetic resonance imaging in intensity-modulated radiotherapy era:the Zhejiang Cancer Hospital\u2032s experience [J]. J Cancer Res Ther 11(6):179\u2013184","journal-title":"J Cancer Res Ther"},{"key":"10329_CR33","doi-asserted-by":"crossref","unstructured":"Ou XM, Zhou X, Shi Q et al Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost [J]. Oncotarget 2015, 6(35): 38381\u201338397","DOI":"10.18632\/oncotarget.5420"},{"key":"10329_CR34","doi-asserted-by":"crossref","unstructured":"Lee AWM, Ng WT, Chan LLK et al Evolution of treatment for nasopharyngeal cancer - success and setback in the intensitymodulated radiotherapy era [J].Radiother Oncol.2014,110( 3): 377\u2013384","DOI":"10.1016\/j.radonc.2014.02.003"},{"issue":"12","key":"10329_CR35","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/bjc.2017.357","volume":"117","author":"A Prawira","year":"2017","unstructured":"Prawira A, Oosting SF, Chen TW et al (2017) Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review[J]. Br J Cancer 117(12):1743\u20131752","journal-title":"Br J Cancer"},{"key":"10329_CR36","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.hoc.2008.08.012","volume":"22","author":"HH Loong","year":"2008","unstructured":"Loong HH, Ma BB, Chan AT (2008) Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer[J]. Hematol Oncol Clin North Am 22:1267\u20131278","journal-title":"Hematol Oncol Clin North Am"},{"key":"10329_CR37","doi-asserted-by":"crossref","unstructured":"Zhang M-X et al (2022) Ting Liu,Rui You,. Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study[J]. Ther Adv Med Oncol.;14:17588359221112486","DOI":"10.1177\/17588359221112486"},{"issue":"4","key":"10329_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","volume":"32","author":"P Bossi","year":"2021","unstructured":"Bossi P, Chan AT, Licitra L et al (2021) Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol 32(4):452\u2013465","journal-title":"Ann Oncol"},{"issue":"7","key":"10329_CR39","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"F-HWX-LW Jifeng","year":"2021","unstructured":"Jifeng F-HWX-LW, Feng et al (2021) Efficacy, Safety, and Correlative Biomarkers of Toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02) [J]. J Clin Oncol 39(7):704\u2013712","journal-title":"J Clin Oncol"},{"key":"10329_CR40","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.oraloncology.2014.01.004","volume":"50","author":"OS Chan","year":"2014","unstructured":"Chan OS, Ngan RK (2014) Individualized treatment in stage IVC nasopharyngeal carcinoma[J]. Oral Oncol 50:791\u2013797","journal-title":"Oral Oncol"},{"issue":"2","key":"10329_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12094-018-1911-7","volume":"21","author":"H Shuang","year":"2019","unstructured":"Shuang H, Feng J, Caineng C et al (2019) The value of radical radiotherapy in the primary tumor of newly diagnosed oligometastatic nasopharyngeal carcinoma patients[J]. Clin Transl Oncol 21(2):213\u2013219","journal-title":"Clin Transl Oncol"},{"key":"10329_CR42","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/cncr.20358","volume":"101","author":"EP Hui","year":"2004","unstructured":"Hui EP, Leung SF, Au JS (2004) Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group[J]. Cancer 101:300\u2013306","journal-title":"Cancer"},{"key":"10329_CR43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.5732\/cjc.010.10098","volume":"29","author":"J Ma","year":"2010","unstructured":"Ma J, Wen ZS, Lin P et al (2010) The results and prognosis of different treatment modalities for solitary metastatic lung tumor from nasopharyngeal carcinoma: a retrospective study of 105 cases[J]. Chin J Cancer 29:787\u2013795","journal-title":"Chin J Cancer"},{"issue":"7","key":"10329_CR44","first-page":"880","volume":"25","author":"SX Wu","year":"2006","unstructured":"Wu SX, Deng ML, Bao Y et al (2006) Therapeutic analysis of stereotactic radiotherapy for 39 patients with lung metastasis[J]. Ai Zheng 25(7):880\u2013884","journal-title":"Ai Zheng"},{"key":"10329_CR45","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1634\/theoncologist.2014-0206","volume":"20","author":"L Shen","year":"2015","unstructured":"Shen L, Dong J, Li S et al (2015) M1 stage subdivision and treatment outcome of patients with boneonly metastasis of nasopharyngeal carcinoma[J]. Oncologist 20:291\u2013298","journal-title":"Oncologist"},{"key":"10329_CR46","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1200\/JCO.2000.18.6.1324","volume":"18","author":"A Fandi","year":"2000","unstructured":"Fandi A, Bachouchi M, Azli N et al (2000) Longterm disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type[J]. J Clin Oncol 18:1324\u20131330","journal-title":"J Clin Oncol"},{"key":"10329_CR47","doi-asserted-by":"publisher","first-page":"101890","DOI":"10.1016\/j.ctrv.2019.101890","volume":"79","author":"AWM Lee","year":"2019","unstructured":"Lee AWM, Ng WT, Chan JYW et al (2019) Management of locally recurrent nasopharyngeal carcinoma[J]. Cancer Treat Rev 79:101890","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10329_CR48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.21037\/cco.2016.03.19","volume":"5","author":"L Kong","year":"2016","unstructured":"Kong L, Lu JJ (2016) Reirradiation of locally recurrent nasopharyngeal cancer: history, advances, and promises for the future[J]. Chin Clin Oncol 5(2):26","journal-title":"Chin Clin Oncol"},{"issue":"3","key":"10329_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2174\/1874467213666191227104646","volume":"13","author":"L Fanghong","year":"2020","unstructured":"Fanghong L, Tongda L, Yun H et al (2020) Radio-susceptibility of nasopharyngeal carcinoma: focus on Epstein-Barr Virus, MicroRNAs, long non-coding RNAs and circular RNAs[J]. Curr Mol Pharmacol 13(3):192\u2013205","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"10329_CR50","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s11671-020-03416-8","volume":"15","author":"P Ya","year":"2020","unstructured":"Ya P, Xiangsheng L, Huowang L et al (2020) TGFBR3 to promote nasopharyngeal carcinoma progression and Tumor Growth via TGF-\u03b2 signaling Pathway[J]. Nanoscale Res Lett 15(1):196","journal-title":"Nanoscale Res Lett"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10329-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:05:13Z","timestamp":1745388313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10329-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["10329"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10329-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5115678\/v1","asserted-by":"object"}]},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}